The use of spa therapy in Estonia commonly consists of courses up to 3-4 weeks in duration for the management of rheumatic diseases. This study sought to evaluate whether there was any difference in the alleviation of patients symptoms between 6 and 12 day courses of spa therapy in the management of osteoarthritis (OA). A total of 296 patients participated in the research. Spa therapies consist of a range of therapies including mud and paraffin-ozokerite applications; pearl baths; underwater shower-massage; manual massage; therapeutic exercises in the gym and in the swimming pool. The aim of this study was not to evaluate the effectiveness of specific therapies but to gain an insight into the length of time required to effect positive symptom relief through the use of a composite spa approach for patients with OA. At the beginning and end of spa treatment, a visual analogue scale (VAS) was determined in all patients and Lequesne Index used for patients with knee and hip osteoarthritis. In both 6 day (group 1) and 12 day (group 2) groups VAS and Lequesne Index decreased significantly. Whilst no significant differences were found when comparing the results of daily spa therapy in both groups 1 and 2, this study suggests that spa therapy has a positive effect by reducing pain and improving clinical status in patients suffering from osteoarthritis.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.ctcp.2007.09.005 | DOI Listing |
Purpose: To evaluate the effect of osilodrostat and hypercortisolism control on blood pressure (BP) and glycemic control in patients with Cushing's disease.
Methods: Pooled analysis of two Phase III osilodrostat studies (LINC 3 and LINC 4), both comprising a 48-week core phase and an optional open-label extension. Changes from baseline in systolic and diastolic BP (SBP and DBP), fasting plasma glucose (FPG), and glycated hemoglobin (HbA) were evaluated during osilodrostat treatment in patients with/without hypertension or diabetes at baseline.
J Neurol
January 2025
Clinical and Molecular Epidemiology, IRCCS San Raffaele Roma, Rome, Italy.
Objectives: To determine whether extending anti-CGRP mAb treatment beyond 3 years influences migraine course, we analyzed migraine frequency during the first month of treatment discontinuation following three 12-month treatment cycles (Ts).
Methods: This multicenter, prospective, real-world study enrolled 212 patients with high-frequency episodic migraine (HFEM) or chronic migraine (CM) who completed three consecutive Ts of subcutaneous anti-CGRP mAbs. Discontinuation periods (D1, D2, D3) were defined as the first month after T1, T2, and T3, respectively.
J Appl Biomater Funct Mater
January 2025
Department of Neurosurgery, Neurocenter of South Switzerland, Ente Ospedaliero Cantonale, Lugano, Switzerland.
Introduction: Intensive research is dedicated to the development of novel biomaterials and medical devices to be used as grafts in reconstructive surgery, with the purpose of enhancing their therapeutic effectiveness, safety, and durability. A variety of biomaterials, from autologous bone to polymethylmetacrylate, polyether ether ketone, titanium, and calcium-based ceramics are used in cranioplasty. Porous hydroxyapatite (PHA) is reported as a possible material for bone reconstruction, with good signs of biocompatibility, osteoconductive and osteointegrative properties.
View Article and Find Full Text PDFNutrients
January 2025
Department of Neurosciences, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health, University of Genoa, 16126 Genoa, Italy.
Background: Migraine, a prevalent neurovascular disorder, affects millions globally and is associated with significant morbidity. Emerging evidence suggests a crucial role of the gut microbiota and adipose tissue in the modulation of migraine pathophysiology, particularly through mechanisms involving neuroinflammation and metabolic regulation.
Material And Methods: A narrative review of the literature from 2000 to 2024 was conducted using the PubMed database.
Int J Mol Sci
January 2025
Clinica Medica "Augusto Murri", Department of Precision and Regenerative Medicine and Ionian Area (DiMePrev-J), University of Bari Aldo Moro, 70124 Bari, Italy.
The integrity of esophageal epithelial cells in patients with gastroesophageal reflux disease (GERD) or GERD-like symptoms is the first mechanism of protection to decrease the sensitivity to gastric reflux and heartburn symptoms. We investigated the protective effects of Poliprotect (PPRO), a CE-marked medical device, on esophageal epithelial integrity using in vitro and ex vivo models. In vitro, the protective effects of PPRO were tested on Caco-2 cells.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!